Lv7
3610 积分 2020-12-07 加入
Real-world evidence of long-term durability and efficacy of faricimab as an advanced treatment line for NVAMD and DME
17小时前
已关闭
Ranibizumab biosimilars vs. reference Ranibizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis
1天前
待确认
Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
2天前
已完结
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration
2天前
已完结
Effectiveness of DIMS combined with atropine and orthokeratology in a real-world setting in China
1个月前
已完结
Myopia control effect of repeated low-level red-light therapy combined with orthokeratology: a multicenter randomized controlled trial
1个月前
已完结
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
2个月前
已完结
Epimacular Brachytherapy for Neovascular Age-related Macular Degeneration (CABERNET)
2个月前
已完结
Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration
2个月前
已完结
Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature
2个月前
已完结
皖公网安备34019202002308
